Related Experiment Video
Updated: Aug 13, 2026
Cell-free Biochemical Fluorometric Enzymatic Assay for High-throughput Measurement of Lipid Peroxidation in High Density Lipoprotein
Published on: October 12, 2017
Hyperlipidemia and coronary disease. Correction of the increased thrombogenic potential with cholesterol reduction
Insights
High cholesterol increases platelet thrombus formation on injured arteries, raising coronary disease risk. Cholesterol reduction with pravastatin significantly decreased this thrombus formation, suggesting a reduced thrombotic risk.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Pharmacology
Background:
- Hypercholesterolemia is a significant risk factor for coronary artery disease.
- Elevated cholesterol levels are associated with increased platelet reactivity, indicating a heightened prethrombotic state.
- Understanding the impact of hypercholesterolemia on arterial thrombus formation is crucial for managing coronary disease risk.
Purpose of the Study:
- To quantify mural platelet thrombus formation on injured arterial walls in hypercholesterolemic patients with coronary disease.
- To assess changes in platelet thrombus formation before and after cholesterol reduction therapy.
- To evaluate the effect of pravastatin on platelet aggregation and lipid profiles in hypercholesterolemic patients.
Main Methods:
- A study involving 32 patients with stable coronary disease, including 16 hypercholesterolemic and 16 normocholesterolemic individuals.
- Measurement of platelet thrombus formation using an ex vivo superfusion chamber with porcine aortic media exposed to patient blood under varying shear rates (754 and 2546 s-1).
- Assessment of serum lipid levels and platelet thrombus morphometry before and after a mean of 2.5 months of pravastatin therapy (40 mg/d) in hypercholesterolemic patients.
Main Results:
- Hypercholesterolemic patients exhibited significantly higher baseline platelet thrombus formation compared to normocholesterolemic controls at both high and low shear rates.
- Pravastatin therapy effectively reduced total cholesterol (6.5 to 4.5 mmol/L) and LDL cholesterol (4.5 to 2.8 mmol/L) in hypercholesterolemic patients (P < .05).
- Following pravastatin treatment, platelet thrombus formation decreased significantly in hypercholesterolemic patients at both high and low shear rates (P < .05).
Conclusions:
- Hypercholesterolemia is directly linked to enhanced platelet thrombus formation on injured arteries, increasing the risk of acute thrombotic events.
- Cholesterol-lowering therapy with pravastatin effectively reduces platelet thrombus formation, mitigating thrombogenic risk.
- Reducing cholesterol levels may be a key strategy in lowering the risk of acute coronary events by decreasing arterial thrombogenicity.
Background:
Hypercholesterolemia is a risk factor for coronary disease, and platelet reactivity is increased with hypercholesterolemia, suggesting a prethrombotic risk. The aim of this study was to measure mural platelet thrombus formation on an injured arterial wall in a model simulating vessel stenosis and plaque rupture in hypercholesterolemic coronary disease patients before and after cholesterol reduction.
Methods And Results:
Thirty-two patients with stable coronary disease were studied. Platelet thrombus formation and serum lipids were measured in 16 hypercholesterolemic patients (cholesterol > 5.2 mmol/L) before and after a mean of 2.5 months of pravastatin therapy (40 mg/d) and in 16 normocholesterolemic control patients. Thrombus formation was assessed by exposing porcine aortic media to the patient's flowing venous blood for 3 minutes at a shear rate of 754 or 2546 s-1 at 37 degrees C in an ex vivo superfusion chamber. Quantitative morphometric platelet thrombus formation at baseline was higher in the hypercholesterolemic patients at both the high and low shear rates: 4.8 +/- 1.0 and 3.3 +/- 0.7 micron 2/mm, respectively, compared with normocholesterolemic patients: 2.1 +/- 0.5 and 1.6 +/- 0.4 micron 2/mm (both P < .05). In the hypercholesterolemic patients, pravastatin decreased total cholesterol from 6.5 +/- 0.2 to 4.5 +/- 0.2 mmol/L and LDL cholesterol from 4.5 +/- 0.2 to 2.8 +/- 0.1 mmol/L (both P < .05). Platelet thrombus formation at high and low shear rates decreased to 2.0 +/- 0.3 and 1.3 +/- 0.3 micron 2/mm, respectively (both P < .05).
Conclusions:
Thus, hypercholesterolemia is associated with an enhanced platelet thrombus formation on an injured artery, increasing the propensity for acute thrombosis. Platelet thrombus formation at both high and low shear rates decreased as total and LDL cholesterol levels were reduced with pravastatin. Cholesterol lowering may therefore reduce the risk of acute coronary events in part by reducing the thrombogenic risk.
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:25Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
01:30Coronary Artery Disease I: Introduction
01:26Coronary Artery Disease II: Pathophysiology
01:26Coronary Artery Disease IV: Preventive Measures
01:26Atherosclerosis III: Management